The major aim is to develop novel strategies to tackle bacterial lung infections caused by P. aeruginosa and S. pneumoniae, focusing on the role of biofilms and persisters underlying antibiotic therapy failure. Novel strategies to treat P. aeruginosa lung cystic fibrosis and ventilator-associated pneumonia (VAP) are studied in in vitro and animal models. For VAP, antimicrobial peptide-based coatings on endotracheal tubes are developed and evaluated. To bridge the gap between in vitro and in vivo, lung-on-a-chip models are under development. In M. tuberculosis, the redox homeostasis is explored as a potential target for novel drugs. For this, knock-out, knock-down and overexpression strains are developed and structural and enzymatic characterization of Mtr is being exploited.